ClearPoint Neuro, Inc. Common Stock (CLPT) — Analysis Summary
ClearPoint Neuro, Inc. Common Stock (CLPT) has a market cap of $478.63M with year-over-year revenue growth of +17.8%. Net margin stands at -69.1%. The stock trades at a P/E ratio of -16.5.
Key Takeaways
- Revenue changed +17.8% year-over-year
- Net margin of -69.1%
- P/E ratio of -16.5
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, CLPT posted revenue growth of +17.8% and trades at a P/E of -16.5.
ClearPoint Neuro, Inc. Common Stock (CLPT)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -7.3x — earnings do not cover interest payments
Operating margin at -65.2% — severe operating losses
Net margin at -71.6% — significant losses
The latest filing shows negative free cash flow.
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
172
Headquarters
SOLANA BEACH, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.